Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
It works by inhibiting NNMT, leading to metabolic changes that can promote the use of fat for energy, reduce fat storage, and potentially slow down cellular aging
About 30 million people in the United States have sleep apnea, according to the American Medical Association, and the condition is more likely to occur in older adults
Een bepaalde hoeveelheid van deze verbinding kun je uit maaltijden halen, omdat het in verschillende voedingsmiddelen wordt aangetroffen
animal) studies Adult animal studies The two most common gas inhalation injuries encountered in emergency departments are carbon monoxide and chlorine inhalations
NOTE: The LVLUP HEALTH brand product line is exclusive to authorized physician retailers and cannot be resold
